Aquestive Therapeutics Financial Statements
NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aquestive Therapeutics revenue and earnings
In fiscal 2025, Aquestive Therapeutics generated $44.5 million in revenue, down 22.6% from fiscal 2024, its first annual decline since 2022. Aquestive Therapeutics reported a net loss of $83.8 million, compared with a loss of $44.1 million a year earlier. Gross margin was 58.3% (down from 69.0%) and operating margin -159.5%.
Diluted earnings per share came in at -$0.78. Over the last 5 fiscal years, AQST's revenue has grown at a -0.6% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Aquestive Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.55M | 57.56M | 50.58M | 47.68M | 50.83M | 45.85M | 52.61M | 67.43M | 66.92M |
| Revenue growth (YoY) | -22.61% | +13.80% | +6.09% | -6.20% | +10.87% | -12.85% | -21.98% | +0.77% | — |
| Cost of Revenue | 18.55M | 17.87M | 20.83M | 19.39M | — | 12.96M | 20.36M | — | — |
| Gross Profit | 25.99M | 39.69M | 29.75M | 28.29M | — | 32.88M | 32.25M | — | — |
| Operating Expenses | 97.04M | 70.46M | 44.85M | 89.75M | 85.51M | 88.74M | 105.28M | 116.37M | 67.03M |
| Research & Development | 17.19M | 20.28M | 13.10M | 17.48M | 17.05M | 19.89M | 20.57M | 23.11M | 22.13M |
| Selling, General & Admin | 79.85M | 50.18M | 31.75M | 52.88M | 53.48M | 55.89M | 64.34M | 72.27M | 25.08M |
| Operating Income | -71.05M | -30.77M | -15.10M | -42.07M | -34.68M | -42.89M | -52.67M | -48.93M | -113.00K |
| Interest Expense | 11.12M | 11.12M | 6.34M | 6.55M | 10.05M | 11.06M | 9.32M | 7.71M | 7.71M |
| Pretax Income | -83.78M | -44.15M | -7.63M | -54.41M | -70.54M | -55.78M | -66.25M | -61.38M | -8.94M |
| Income Tax | 0 | -14.00K | 245.00K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -83.78M | -44.14M | -7.87M | -54.41M | -70.54M | -55.78M | -66.25M | -61.38M | -8.94M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 | -1.66 | -2.61 | -2.96 | — |
| EPS (Diluted) | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 | -1.66 | -2.61 | -2.96 | — |
| Shares Outstanding (Basic) | 106.93M | 86.73M | 61.26M | 48.73M | 38.08M | 33.65M | 25.36M | 20.73M | — |
| Shares Outstanding (Diluted) | 106.93M | 86.73M | 61.26M | 48.73M | 38.08M | 33.65M | 25.36M | 20.73M | — |
| EBITDA | -70.50M | -30.05M | -13.76M | -39.68M | -31.71M | -39.45M | -49.76M | -45.75M | 3.64M |
| Gross Margin | 58.35% | 68.95% | 58.82% | 59.34% | — | 71.72% | 61.30% | — | — |
| Operating Margin | -159.50% | -53.46% | -29.86% | -88.23% | -68.22% | -93.55% | -100.11% | -72.57% | -17.00% |
| Net Margin | -188.09% | -76.68% | -15.56% | -114.11% | -138.77% | -121.67% | -125.92% | -91.02% | -13.36% |
This table shows 9 annual periods of Aquestive Therapeutics's income statement, from FY 2025 back to FY 2017, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AQST's reporting calendar. What is a income statement?